Lineage Cell Therapeutics

LCTX54

Penny Stock

$0.94arrow_drop_up3.29%$0.03

Penny Stock

LCTX54

$0.94

arrow_drop_up3.29%$0.03

Penny Stock

Performance History

Key Stats
Open	$0.90
Prev. Close	$0.88
EPS	-0.13
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$166.17M
PE Ratio	-

	LOW	HIGH
Day Range	0.89	0.91
52 Week Range	0.77	1.61

Ratios







EPS	-0.13

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Lineage Cell Therapeutics (LCTX)

Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company focused on developing and commercializing innovative cell-based therapies for the treatment of degenerative diseases. The company's primary focus is on developing therapies based on its proprietary cell replacement and modulation platform technologies. These technologies have the potential to revolutionize the treatment of diseases such as age-related macular degeneration, spinal cord injury, and chronic kidney disease.

The history of Lineage Cell Therapeutics Inc can be traced back to its founding in 1990 as BioTime Inc. Over the years, the company has undergone several name changes and strategic shifts, culminating in its current focus on cell-based therapies. The company's stock price history reflects this evolution, with periods of volatility and growth as the company has progressed through its various stages of development.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Brian M. Culley M.A., M.B.A.
Headquarters: Carlsbad
Employees: 70
Exchange: NYSE

add Lineage Cell Therapeutics to watchlist

Keep an eye on Lineage Cell Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Lineage Cell Therapeutics 's (LCTX) price per share?

The current price per share for Lineage Cell Therapeutics (LCTX) is $0.94. The stock has seen a price change of $0.03 recently, indicating a 3.3% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Lineage Cell Therapeutics (LCTX)?

For Lineage Cell Therapeutics (LCTX), the 52-week high is $1.61, which is 71.28% from the current price. The 52-week low is $0.77, the current price is 22.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Lineage Cell Therapeutics (LCTX) a growth stock?

Lineage Cell Therapeutics (LCTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 25 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lineage Cell Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Lineage Cell Therapeutics (LCTX) stock price performance year to date (YTD)?

As of the latest data, Lineage Cell Therapeutics (LCTX) has a year-to-date price change of -13.76%. Over the past month, the stock has experienced a price change of 8.01%. Over the last three months, the change has been 5.12%. Over the past six months, the figure is -22.95%. Looking at a longer horizon, the five-year price change stands at -12.15%.

help

Is Lineage Cell Therapeutics (LCTX) a profitable company?

Lineage Cell Therapeutics (LCTX) has a net income of -$21.49M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 84.76% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -416.69% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $8.94M, although specific revenue growth data is currently not available. The gross profit is $7.58M. Operating income is noted at -$24.73M. Furthermore, the EBITDA is -$21.4M.

help

What is the market capitalization of Lineage Cell Therapeutics (LCTX)?

Lineage Cell Therapeutics (LCTX) has a market capitalization of $177.51M. The average daily trading volume is 365.11K, indicating the stock's liquidity and investor engagement.